100 related articles for article (PubMed ID: 3334664)
41. [Questions on hormone and chemotherapy in metastatic breast cancer].
Brunner KW
Gynakol Rundsch; 1988; 28 Suppl 1():76-83. PubMed ID: 3042537
[No Abstract] [Full Text] [Related]
42. Analysis of time to response to chemotherapy in 316 metastatic breast cancer patients.
Pronzato P; Bertelli G; Gardin G; Rubagotti A; Conte PF; Rosso R
Oncology; 1993; 50(6):460-5. PubMed ID: 8233288
[TBL] [Abstract][Full Text] [Related]
43. Combination chemotherapy with cyclophosphamide, mitoxantrone and 5-fluorouracil in patients with metastatic breast cancer.
Yap HY; Esparza L; Blumenschein GR; Hortobagyi GN; Bodey GP
Cancer Treat Rev; 1983 Dec; 10 Suppl B():53-5. PubMed ID: 6661735
[No Abstract] [Full Text] [Related]
44. [Importance of the composition of various combination regimens in the chemotherapy of metastatic breast cancer].
Petru E; Schmähl D
Dtsch Med Wochenschr; 1987 Feb; 112(7):270-5. PubMed ID: 3545749
[No Abstract] [Full Text] [Related]
45. Randomized clinical trials in breast cancer: a tabular summary. Part 2: Advanced breast cancer.
Kieser R; Conrad B
Arch Geschwulstforsch; 1987; 57(4):323-49. PubMed ID: 3314771
[No Abstract] [Full Text] [Related]
46. Chemotherapy regimens in metastatic breast cancer.
Glück S
Clin Adv Hematol Oncol; 2011 Jan; 9(1):47-8. PubMed ID: 21326146
[No Abstract] [Full Text] [Related]
47. Clinical trials referral resource. Breast cancer.
Cheson BD
Oncology (Williston Park); 1991 Jul; 5(7):115-31. PubMed ID: 1837472
[No Abstract] [Full Text] [Related]
48. Generalised seizures following ondansetron.
Sharma A; Raina V
Ann Oncol; 2001 Jan; 12(1):131-2. PubMed ID: 11249042
[No Abstract] [Full Text] [Related]
49. Anthracycline-induced cardiomyopathy in siblings with early breast cancer.
Young AC; Mercer B; Perren TJ; Dodwell D
Ann Oncol; 2011 Jul; 22(7):1692. PubMed ID: 21555361
[No Abstract] [Full Text] [Related]
50. Interpretation of results of chemotherapy trials in metastatic breast cancer.
J Clin Oncol; 1986 Feb; 4(2):258-61. PubMed ID: 3511185
[No Abstract] [Full Text] [Related]
51. Hormone priming in breast cancer: oestrogen priming has a detrimental effect on response in oestrogen receptor-negative patients.
Seymour L; Meyer K; Bezwoda WR
Eur J Cancer; 1993; 29A(10):1495-6. PubMed ID: 8398282
[No Abstract] [Full Text] [Related]
52. Metastatic astrocytoma in the parotid.
Raut V; Golchin K; Anderson N; Primrose WJ
Cytopathology; 2002 Jun; 13(3):186-8. PubMed ID: 12060086
[No Abstract] [Full Text] [Related]
53. Chemotherapy of advanced breast cancer.
Herrmann R
J Clin Oncol; 1988 Oct; 6(10):1665-6. PubMed ID: 3171632
[No Abstract] [Full Text] [Related]
54. Hexamethylmelamine use in the treatment of metastatic breast cancer.
Henderson IC; Shapiro CL
Cancer Treat Rev; 1991 Mar; 18 Suppl A():91-8. PubMed ID: 1904313
[No Abstract] [Full Text] [Related]
55. Rubidazone in metastatic breast cancer.
Legha SS; Benjamin RS; Buzdar AU; Hortobagyi GN; Blumenschein GR
Cancer Treat Rep; 1979 Jan; 63(1):135-6. PubMed ID: 369685
[No Abstract] [Full Text] [Related]
56. Innumerable variations: combining biologics.
Sledge GW
Clin Breast Cancer; 2009 Feb; 9(1):7. PubMed ID: 19299233
[No Abstract] [Full Text] [Related]
57. First-line systemic therapy for metastatic breast cancer and management of pleural effusion.
Perrone F; Carlomagno C; De Placido S; Lauria R; Morabito A; Bianco AR
Ann Oncol; 1995 Dec; 6(10):1033-43. PubMed ID: 8750157
[No Abstract] [Full Text] [Related]
58. Controversy over cancer chemotherapy in Japan.
Kawabata H; Ueno T
Lancet; 1999 Jun; 353(9169):2077. PubMed ID: 10376656
[No Abstract] [Full Text] [Related]
59. Selected clinical trials in breast cancer.
Clin Breast Cancer; 2006 Feb; 6(6):540-1. PubMed ID: 16612874
[No Abstract] [Full Text] [Related]
60. Current and future trends in the multidisciplinary approach for high-risk breast cancer. The experience of the Milan Cancer Institute.
Bonadonna G
Eur J Cancer; 1996 Feb; 32A(2):209-14. PubMed ID: 8664029
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
